Conference Coverage

‘Hidden’ cognitive impairments in DMD may worsen outcomes


 

FROM AANEM 2023

Overcoming a significant barrier

The NIH Toolbox has a lot of potential to improve DMD care, according to Dianna Quan, MD, who is the incoming president of AANEM, and professor of neurology at the University of Colorado at Denver, Aurora. “There’s this huge problem in terms of getting people in to see neuropsychologists and having formal evaluations. I think that’s a huge barrier. If we have people able to access this toolkit, which is simple and easily and universally accessible, how wonderful is that? I think that will be a really great improvement on what’s going on right now. It allows people to easily screen for these cognitive disabilities and make sure that we address them,” Dr. Quan said in an interview.

Asked how the tool could specifically improve care, Dr. Quan suggested that the first step is to understand the contributing factors to cognitive issues, whether they are biological, social, or a combination. “Some of them we can modify, potentially, through addressing the social environment. Some of those biologic factors may also be modifiable with many of the new drug studies that are coming.”

Dr. Thangarajh has received speaker honoraria from NS Pharma and PTC Therapeutics. Dr. Quan has received funding from Alnylam, Pfizer, Cytokinetics, Momenta, and Argenx.

Pages

Recommended Reading

Are cellular therapies the future of autoimmune disease?
MDedge Neurology
Emerging therapies in Duchenne and facioscapulohumeral muscular dystrophy
MDedge Neurology
Has prompt diagnosis of amyotrophic lateral sclerosis become urgent?
MDedge Neurology
The dawning age of therapy for Friedreich ataxia
MDedge Neurology
Stiff person syndrome: When a rare disorder hits the headlines
MDedge Neurology
FDA okays drug for Duchenne muscular dystrophy
MDedge Neurology
In myasthenia gravis, antibodies pass open-label tests
MDedge Neurology
Genetic therapies bring change to neurology clinics
MDedge Neurology
Duchenne muscular dystrophy gene therapy safe, effective at 4 years
MDedge Neurology
First new treatment in 30 years for rare disease is effective, tolerable, convenient
MDedge Neurology